Chemotherapy and targeted agents for elderly women with advanced breast cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 3, 2008, Pages 187-201

  Brunello, Antonella ^a   Roma, Anna ^a   Falci, Cristina ^a   Basso, Umberto ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bevacizumab; Breast cancer; Capecitabine; Chemotherapy; Docetaxel; Elderly; Gemcitabine; Idarubicin; Paclitaxel; Pegylated liposomal doxorubicin; Protein bound paclitaxel; Trastuzumab; Vinorelbine

Indexed keywords

ALBUMIN; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CORTICOSTEROID; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FUROSEMIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IDARUBICIN; IDARUBICINOL; NANOPARTICLE; NAVELBINE; PACLITAXEL; SPIRONOLACTONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BLOOD VESSEL PERMEABILITY; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST CANCER; BRONCHOSPASM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CINCA SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UPTAKE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLOMERULONEPHRITIS; HAND FOOT SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG HEMORRHAGE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PATENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; QUALITY OF LIFE INDEX; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR RESISTANCE; WEIGHT GAIN;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 58049198447     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208786242313     Document Type: Article

References (167)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4-S66.
2. Hunt KK, Mendelsohn J, Eds. Bevers, Primary Prevention of Breast Cancer, in Breast Cancer 2001; 20-54.
3. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49(8): 1-113.
4. Kimmick GG, Balducci L. Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am 2000; 14(1): 213-234.
5. Ries LAG, Harkins D, Krapcho M, et al. Cancer Statistics Review 1975_2003. National Cancer Institute, Bethesda. Available at: http://seer.cancer.gov/csr/1975_2003/. Accessed February 2008.
6. Freyer G, Braud AC, Chaibi P, et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the "Observatory on Elderly Patients". Ann Oncol 2006; 17(2): 211-216.
7. Surveillance, Epidemiology, and End Results (SEER) Program available at www.seer.cancer.gov. Public Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002.
8. Greene FL, Page DL, Fleming ID, et al., Eds. AJCC Cancer Staging Manual, 6th ed., 2002.
9. Holmes CA, Muss HB. Diagnosis and treatment of breast cancer in the elderly. CA Cancer J Clin 2003; 53(4): 227-244.
10. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003; 8(6): 514-520.
11. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002; 7(6): 13-19.
12. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-374.
13. von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997; 2: S13-3-S13-10,
14. Joyce C. Taxol: search for a cancer drug. Bioscience 1993; 43(3): 133-136.
15. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994; 344(8932): 1267-1272.
16. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123-130.
17. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004; 99(2): 3-8.
18. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere) a semi-synthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-291.
19. Tinwell H, Ashby J. Genetic toxicity and potential carcinogenicity of taxol. Carcinogenesis 1994; 15: 1499-1501.
20. Childs S, Ling V. The MDR superfamily of genes and its biological implications. Important Adv Oncol 1994: 21-36.
21. Galmarini CM, Kamath K, Vanier-Viornery A et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88: 1793-1799.
22. Maney T, Wagenbach M, Wordeman L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J Biol Chem 2001; 276: 34753-34758.
23. Bonnet C, Boucher D, Lazereg S, et al. Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J Biol Chem 2001; 276: 12839-12848.
24. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003; 63: 1207-1213.
25. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-1070.
26. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-5809.
27. Horwitz SB. Taxol (paclitaxel) mechanisms of action. Ann Oncol 1994; 5(6): S3-6.
28. Goodman J, Walsh V. The story of taxol nature and politics in the pursuit of an Anti-Cancer Drug. Cambridge University Press, 2001
29. Prod Info TAXOL(R) intravenous injection, 2003.
30. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of Paclitaxel. Clin Pharmacokinet 1994; 27: 256-269.
31. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 Paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-575.
32. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995; 23: 506-512.
33. Henningsson A, Vigano L, Karlsson MO, et al. Mechanism-based pharmacokinetic model for Paclitaxel. J Clin Oncol 2001; 19: 4065-4073.
34. Pasquier E, Carré M, Purroy B, et al. Antiangiogenic activity of Paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004; 3(10): 1301-1310.
35. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004; 30(4): 333-342.
36. Smorenburg CH, Ten, TAJ, Verweij J, et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003; 39(2): 196-202.
37. Ten TAJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004; 40(3): 352-357.
38. Del Mastro ML, Perrone F, Repetto L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005; 16(2): 253-258.
39. "Abraxane Drug Information." Food and Drug Administration. January 7, 2005. Retrieved on March 9, 2007.
40. Desai, N.P., Soon-Shiong, P.: WO08057562 (2008).
41. Gradishar WJ. Albumin-bound paclitaxel a next-generation taxane. Expert Opin Pharmacother 2006; 7(8): 1041-1053.
42. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7(11): 850-856.
43. Lyseng-Williamson KA, Fenton C. Docetaxel a review of its use in metastatic breast cancer. Drugs 2005; 65(17): 2513-2531.
44. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36(2): 99-114.
45. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in b-tubulin A model based on electron crystallographic density. Proc Natl Acad Sci USA 2001; 98(9): 5312-5316.
46. Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids paclitaxel (Taxol(R)) and docetaxel (Taxotere(R)). Cancer Treat Rev 1993; 19: 351-386.
47. Product Information TAXOTERE® IV injection, Docetaxel IV injection. Sanofi-Aventis US LLC, Bridgewater, NJ, 2006.
48. Bissett D, Kaye SB. Taxol and taxotere-current status and future prospects. Eur J Cancer 1993; 29: 1228-1231.
49. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of taxotere five-day schedule. J Natl Cancer Inst 1992; 84: 1781-1788.
50. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993; 11: 950-958.
51. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-1042.
52. Chan S, Winterbottom L, Gardner S. Response to dexamethasone in patients with fluid retention after docetaxel. Lancet 1996; 347(9013): 1486-1487.
53. Zanetta S, Albrand G, Bachelot T, et al. A phase I trial of docetaxel every 21 days in elderly patients with metastatic breast cancer (MBC). Proc 25th Congress of the European Society for Medical Oncology. Ann Oncol 2000; 11 (Suppl 4): 73.
54. Lorenzo I, Constenla M, Palacios P, et al. Docetaxel as single-agent treatment in elderly patients with advanced breast cancer. Clin Drug Investig 2005; 25(4): 249-256.
55. Hamberg P, Verweij J, Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: A review on safety, pharmacokinetics and efficacy. Eur J Cancer 2007; 43(10): 1514-1528.
56. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19(15): 3500-3505.
57. Massacesi C, Marcucci F, Boccetti T, et al. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. J Exp Clin Cancer Res 2005; 24(1): 43-48.
58. Toso C, Lindley C. Vinorelbine a novel vinca alkaloid. Am J Health Syst Pharm 1995; 52(12): 1287-1304.
59. Feigal EG, Christian M, Cheson B, et al. New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 1993; 20: 185-201.
60. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of Navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991; 51: 2073-2076.
61. Marquet P, Lachatre G, Debord J, et al. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992; 42: 545-547.
62. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33(2): 301-303.
63. Baweja M, Suman VJ, Fitch TR, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ≥65 years of age an NCCTG study. Ann Oncol 2006; 17: 623-629.
64. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10(4): 397-402.
65. Addeo R, Faiola V, Guarrasi R, et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women >/=65 years of age. Cancer Chemother Pharmacol 2008; 62(2): 285-292.
66. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19(10): 2722-2730.
67. Walko CM, Lindley C. Capecitabine a review. Clin Ther 2005; 27: 23-44.
68. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate Capecitabine. J Clin Oncol 1998; 16: 1795-1802.
69. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
70. Sobrero A, Guglielmi A, Grossi F, et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000; 27(10): 72-77.
71. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16: 2977-2985.
72. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43(1): 14-34.
73. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12(9): 1247-1254.
74. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23(10): 2155-2161.
75. Hess D, Thurlimann B, Pagani O, et al. Capecitabine and vinorelbine in elderly patients (> or = 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004; 15(12): 1760-1765.
76. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-4422.
77. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17(5): 7-12.
78. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997; 24(7): 72-77.
79. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-262.
80. Grunewald R, Kantarjian H, Du M, et al. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-413.
81. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: pharmacology and mechanisms of action. Semin Oncol 1996; 23(10): 3-15.
82. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58(19): 4349-4357.
83. Achiwa H, Oguri T, Sato S, et al. Determinants of sensitivity and resistance to gemcitabine the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-757.
84. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956-6961.
85. Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer a multicenter, randomized, phase III study. Ann Oncol 2005; 16(6): 899-908.
86. Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 90(3): 215-221.
87. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64: 191-206.
88. Melemed AS, O'Shaughnessy J, Nag S, et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. Proceedings of ASCO Breast Cancer Symposium. 2009
89. Basso U, Fratino L, Brunello A, et al. Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study. Ann Oncol 2007; 18(1): 58-63.
90. Dinota A, Bilancia D, Romano R, Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 2005; 89(1): 1-3.
91. Martin M, Ruiz A, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8(3): 219-225.
92. Budman DR, Calabro A, Kreis W. in vitro Evaluation of synergism or antagonism with combinations of new cytotoxic agents. Antican Drugs 1998; 9: 697-702.
93. De Luca A, Grassi M, Maiello MR, et al. Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? Antican Res 2004; 24: 2985-2990.
94. Cattel L, Airoldi M, Passera R, et al. Gemcitabine plus vinorelbine chemotherapy regimens: A pharmacokinetic study of alternate administration sequences. Pharm World Sci 2004; 26: 230-241.
95. Hortobagyi GN. Anthracyclines in the treatment of cancer: Drugs 1997; 54(4): 1-7.
96. Zunino F, Capranico G. DNA topoisomerasis II as the primary target of antitumoral anthracyclines. Antican Drug Des 1992 5: 307-317.
97. Friche E, Skovsgaardt T, Nissen JI. Anthracycline resistance. Acta Oncologica 1989; 28: 877-881.
98. Speth PAJ, Minderman H, Haanen C. Idarubicin v daunorubicin: Preclinical and clinical pharmacokinetic studies. Semin Oncol 1989; 16(2): 2-9.
99. Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 15; 64(12): 2431-2436.
100. Supino R, Necco A, Dasdia T, et al. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res1977; 37(12): 4523-4528.
101. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275-288.
102. Chevallier B, Monnier A, Metz R, et al. Phase II study of oral idarubicin in elderly patients with advanced breast cancer. Am J Clin Oncol 1990 Oct; 13(5): 436-439.
103. Crivellari D, Lombardi D, Corona C, et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006; 17(5): 807-812.
104. Mouridsen HT, Alfthan C, Bastholt L, et al: Current status of epirubicin (farmorubicin) in the treatment of solid tumours. Acta Oncologica 1990; 29: 257-285.
105. Tjuljandin SA, Doig RG, Sobol MM, et al. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 1990; 50: 5095-5101.
106. Product Information: Ellence (R), epirubicin. Pharmacia & Upjohn, Bently, WA, USA, Rev, 2003.
107. Mross K, Maessen P, van der Vijgh WJF, et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517-526.
108. Nicolella D, Giuseppe G, Colantuoni G, et al. Weekly low dose epirubicin in elderly cancer patients. Tumori 1996, 82: 369-371.
109. http://www.fda.gov/cder/foi/label/1999/50718s06lbl.pdf
110. Swain SM, Whaley F, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97: 2968-2879.
111. Gabizon AA, Lyass O, Berry GJ, et al. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22: 663-669.
112. 2. Ann Oncol 2000; 11: 1029-1033.
113. O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003; 4(5): 318-328.
114. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
115. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893-3901.
116. Biganzoli L, Coleman R, Minisini A, et al. Joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007; 61: 84-89.
117. Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249-3254.
118. Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15: 891-895.
119. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16(7): 2445-2451.
120. Sehouli J, Oskay-Ozcelik G, Kahne J, et al. Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 2006; 17: 957-961.
121. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7: 548-552.
122. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006; 232: 123-138.
123. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001; 28(16): 4-11.
124. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin Oncol 1999; 26(12): 60-70.
125. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by Trastuzumab, and loss of PTEN predicts Trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
126. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 30; 94(2): 259-267.
127. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280.
128. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways implications for HER2-targeted antibody therapy. Oncogene 2006.
129. Klos KS, Zhou X, Lee S, et al. Combined Trastuzumab and Paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98: 1377-1385.
130. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
131. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
132. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
133. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002; 99: 783-791.
134. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857.
135. Pupa SM, Menard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993; 8: 2917-2923.
136. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6: 2356-2362.
137. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-1135.
138. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 2518-2525.
139. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
140. Esteva FJ, Cheli C, Fritsche HA, et al. Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing Trastuzumab-based therapy. Breast Can Res Treat 2004; 88: 6001.
141. Kostler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/ neu predicts response and progression-free survival to Trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 1618-1624.
142. http://www.accessdata.fda.gov/scripts/cder/onctools/ labels.cfm?GN=trastuzumab
143. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 118(11): 2350-2351.
144. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
145. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: Recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8(12): 1101-1115.
146. Brunello A, Basso U, Pogliani C, et al. Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients. Ann Oncol 2005; 16(8): 1276-1282.
147. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 15; 344(11): 783-792.
148. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 15; 19(10): 2722-2730.
149. Paton VE, Klein P, Lieberman G. Trastuzumab (H) benefits both younger and older women with HER2 positive MBC. Proc Am Soc Clin Oncol 2003; 22
150. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
151. Giuliani R, Minisini AM, Paesmans M, et al. Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2004 ASCO Annual Meeting Proc 2004; 22(14S): 838.
152. Fyfe G, Mass R, Murphy M, Slamon D. Older (age>60) patients obtain survival benefit from herceptln plus chemotherapy. Eur J Cancer 2001; 37: S189.
153. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20(5): 1215-1221.
154. Brunello A, Monfardini S, Crivellari D, et al. Multicenter analysis of activity and safety of Trastuzumab plus chemotherapy in advanced breast cancer in elderly women (≥ 70 years). Proc ASCO Annual Meeting 2008
155. O'Shaughnessy J, Blackwell L, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO Annual Meeting 2008
156. Von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO Annual Meeting 2008
157. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.
158. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65(3): 671-680.
159. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy a new paradigm for combination therapy. Nat Med 2001; 7(9): 987-989.
160. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19: 4203-4214.
161. Gordon MS, Margolin K, Talpaz G, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
162. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288: 337-371.
163. http://www.fda.gov/cder/foi/label/2004/125085lbl.pdf
164. http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/H-582-PI-it.pdf
165. Cobleigh M, Miller K, Langmuir V, et al. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2001; 69: 301.
166. Kushner, P., Goldfine, I., Hodges-Gallagher, L., Valentine, C.: WO08027837 (2008).
167. Patel, B.K.: EP1913947 (2008).